SUBOXONE News

From In INDIVIOR

Important Program Update

May 2022

On May 3, 2022, the FDA approved a REMS Modification, and SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX tablets are now covered under the Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) REMS Program.

For more information about the BTOD REMS, including all program materials and instructions visit www.btodrems.com or call 1-855-223-3922.

General information about buprenorphine treatment and the treatment of addiction are available through numerous sources, including, including but not limited to:

SAMHSA website (www.samhsa.gov)

American Society of Addiction Medicine website (www.asam.org)

American Academy of Addiction Psychiatry website (www.aaap.org)